|
|
 |
|
¡¡ |
|
¡¡ |
|
|
|
¡¡ |
HOME > ÇÐȸ°£Ç๰ >
¿ë¾î»çÀü |
|
Á¦¸ñ |
A STUDY ON RELAPSE IN FOLLOW-UP CASES AFTER COMPLETION OF MULTIDRUG THERAPY |
|
|
|
|
ÀúÀÚ |
Sung Jun Choi |
¼Ò¼Ó |
Institute for Leprosy Research, KLCA |
|
|
³âµµ |
1990 |
±Ç |
23 |
|
|
È£ |
1 |
¹øÈ£ |
|
|
|
½ÃÀÛÆäÀÌÁö |
55 |
³¡ÆäÀÌÁö |
59 |
|
|
÷ºÎ |
|
|
|
¿ä¾à |
This study is a follow-up of 55 leprosy patients on MDT who were released from treatment. Patients who had been released from treatment were re-examined clinically and bacteriologically every 6 months for 6 to 78 months (average duration 2 years and 11 months) and following results were obtained. 1. There was no relapse case in 27 MB cases. 2. There were 2 patients who had relapsed (7%) in 28 PB cases, and relapses occurred 10 months and 20 months after completion of MDT subsequently. 3. There were 3 BT cases which were positive in skin smear (BI 1+) at the initiation of MDT in 28 PB cases. Of those 3 cases, 2 cases relapsed. So it would be better to classify BI 1+ cases as multibacillary type as WHO Experty committee on Leprosy recommended. 4. One of the 2 relapsed BT cases had multiple macular lesions and multiple involvement of peripheral nerves at the initiation of MDT. So in this variety of BT leprosy, classification should therefore be undertaken only after careful consideration of all clinical features and careful follow-up should be done for occurrence of reversal reactions and/or relapse. 5. Durations of MDT in 2 relapsed case were 26 months and 42 months. So implementation of MDT for 6 months in PB seems to be not enough. |
|
|
³»¿ë |
|
 | |
¡¡ |
|
|
|
|
|
|
|
|